UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE ~~SECURITIES EXCHANGE ACT OF 1934~~

~~Date~~SECURITIES ofEXCHANGE ~~report~~ACT ~~(Date~~OF ~~of earliest event reported): November 30, 2023~~1934

Date of report (Date of earliest event reported): December 15, 2023

DMK PHARMACEUTICALS CORPORATION

(Exact Name of Registrant as Specified in its Charter)

Delaware		0-26372		82-0429727
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

11622 El Camino Real, Suite 100

San Diego, CA

92130

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (858) 997-2400

(Former ~~name~~Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		DMK		NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 51.0702 ~~Submission~~Termination of ~~Matters to~~ a ~~Vote~~Material ofDefinitive ~~Security Holders~~Agreement.

~~The~~Effective ~~disclosures~~December ~~under~~15, ~~Item~~2023, the 8distribution and commercialization contract between DMK Pharmaceuticals Corporation (the “Company”) and USWM, LLC (“US WorldMeds”) was terminated.01 ~~below~~US ~~are~~WorldMeds ~~incorporated~~previously held exclusive distribution and commercialization rights for the Company’s ~~herein~~SYMJEPI by(epinephrine) ~~reference~~and ZIMHI (naloxone) products in the United States, and was responsible for marketing, promotion and distribution efforts. The distribution agreement between the Company and US WorldMeds previously was terminated as to the ~~extent~~Company’s ~~applicable~~SYMJEPI products, and now is terminated as to the Company’s ZIMHI product, as well.

Item 8.01 Other Events.

~~The~~On ~~2023~~December ~~annual~~21, ~~meeting of~~2023, ~~stockholders (~~the ~~“Annual Meeting”) of DMK Pharmaceuticals Corporation (the “~~Company~~”), originally convened~~ onissued ~~November~~a 9,press ~~2023,~~release ~~was~~regarding ~~reconvened~~the ~~virtually~~termination onof ~~November 30, 2023. The Company adjourned~~ the ~~Annual~~US ~~Meeting~~WorldMeds ~~again~~contract toreturning ~~allow additional time for~~ the ~~Company~~rights to ~~solicit~~distribute ~~additional proxies~~ and ~~votes~~commercialize ZIMHI to ~~establish~~the aCompany. ~~quorum~~A ~~for~~copy ~~the conduct~~ of ~~business at~~ the ~~Annual Meeting and additional time for stockholders to vote on the proposals described in the~~ Company’s ~~notice~~press ofrelease ~~meeting~~announcing ~~and~~this ~~definitive~~information ~~proxy~~and ~~statement filed~~certain ~~with~~other ~~the~~information ~~Securities~~is ~~and~~attached ~~Exchange~~hereto as ~~Commission~~Exhibit ~~(the~~99.1 ~~“SEC”)~~and onis ~~October~~incorporated ~~12,~~herein ~~2023~~by ~~(the “Proxy Statement”)~~reference.

The ~~adjourned~~information ~~Annual~~included ~~Meeting will~~in ~~reconvene~~Item on2.02 ~~December~~(including ~~28,~~Exhibit at99.1) ~~9:00~~of ~~a.m.,~~this Current ~~Pacific~~Report ~~Time. The~~on ~~adjourned~~Form ~~Annual~~8-K ~~Meeting~~shall ~~will~~not be adeemed ~~completely~~ “~~virtual~~filed” ~~meeting~~ offor ~~stockholders,~~purposes ~~and~~of ~~stockholders~~Section 18 ~~will~~of bethe ~~able~~Securities toExchange ~~listen~~Act ~~and~~of 1934 ~~participate in~~ (the ~~virtual~~“Exchange ~~meeting~~Act”), asor ~~well~~otherwise assubject ~~vote~~to ~~during~~ the ~~live webcast~~liabilities of ~~the~~that ~~meeting~~section, bynor ~~visiting www.virtualshareholdermeeting.com/DMK2023. To~~shall ~~participate~~it inbe ~~the~~deemed ~~virtual~~incorporated ~~Annual~~by ~~Meeting,~~reference ~~stockholders~~in ~~will~~any ~~need~~filing under the ~~control~~Securities ~~number~~Act ~~found~~of on1933 ~~their proxy cards~~ or in the ~~instructions~~Exchange ~~that~~Act, ~~accompanied~~whether ~~their~~made ~~proxy~~before ~~materials. Only stockholders~~or ofafter ~~record on~~ the ~~record~~ date hereof, regardless of ~~October~~any 6,general ~~2023,~~incorporation ~~are~~language ~~entitled~~in tosuch ~~vote~~filing.

~~Important~~Item ~~Information~~9.01 Financial Statements and Exhibits

In connection with the solicitation of proxies for the Annual Meeting, the Company filed the Proxy Statement with the SEC. The Company’s stockholders are strongly advised to read the definitive proxy materials, as supplemented, and any other relevant solicitation materials filed by the Company with the SEC before making any voting decision because these documents contain important information. The Proxy Statement and any other materials filed by the Company with the SEC can be obtained free of charge at the SEC’s website at www.sec.gov.

Exhibit No.	Description
99.1	Press Release issued December 21, 2023.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	DMK PHARMACEUTICALS CORPORATION
Dated: December 4, 2023	By:	/s/ Seth A. Cohen
Dated: December 21, 2023	By:	/s/ Seth A. Cohen
	Name:	Seth A. Cohen
	Title:	Chief Financial Officer

Filing Compare · DMK PHARMACEUTICALS Corp